Anti-Covid pill likely to be approved in India soon .

The Drugs Controller General of India is reviewing the clinical data of molnupiravir, the world’s first anti-Covid pill approved in the United Kingdom, for the treatment of Covid-19 in adults in India. Sun Pharmaceutical Industries said it is all set to introduce Merck Sharp Dohme (MSD) and Ridgeback’s molnupiravir under the brand name Molxvir.

Sun Pharma is one of the companies in India with which Merck entered into voluntary licensing agreements.

“The recent authorisation of molnupiravir, licensed from MSD and Ridgeback, by the UK regulator is a positive step. In line with our consistent efforts to accelerate access to new drugs for COVID-19 treatment, we are gearing up to make Molxvir available to patients and healthcare providers across India at an economical price post-approval by DCGI,” Sun Pharma India Business CEO Kirti Ganorkar said in a statement.

Molnupiravir, as a small molecule, does not require cold storage like messenger RNA vaccines. In the Phase 3 trial by Merck, Molnupiravir significantly reduced the risk of hospitalisation or death by around 50 per cent in a planned interim analysis of the MOVe-OUT trial in at risk, non-hospitalised adult patients with mild-to-moderate COVID-19.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button